Tech Company Financing Transactions
GlycoEra Funding Round
On 5/27/2025, GlycoEra raised $130 million in Series B funding from Novo Holdings, Bristol Myers Squibb and Catalio Capital Management.
Transaction Overview
Company Name
Announced On
5/27/2025
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series B
Investors
Proceeds Purpose
The Series B cash will be used to test GE8820 in clinical trials and bring a second program to the clinic.
Company Information
Company Status
Private & Independent
Industry
AgTech
Mailing Address
Einsiedlerstrasse 34
Wädenswil, 8820
Switzerland
Wädenswil, 8820
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ganesh Kaundinya
Chief Scientific Officer
Tanmoy Ganguly
Chief Technical Officer
Manuela Mally
VP - Bus. Development
Greg Fralish
VP - Finance
Daniel Rodel
VP - Manufacturing
Dominique Sirena
Browse more venture capital transactions:
Prev: 5/27/2025: Hormona venture capital transaction
Next: 5/27/2025: SCI Semiconductor venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs